YINGLONG: A Multicenter, Prospective, Non-Interventional Study Evaluating the Safety and Tolerability of Ticagrelor in Chinese Patients with Acute Coronary Syndrome

INTRODUCTION: Ticagrelor is an oral, reversible, direct-acting P2Y(12) receptor inhibitor approved for the prevention of cardiovascular events in acute coronary syndrome (ACS). In China, drug intensive monitoring regulations for new drugs require additional safety data post-approval. METHODS: YINGLO...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Adv Ther
Autori principali: Du, Xin, Zheng, Yang, Yang, Ping, Ma, Shuren, Yu, Zaixin, Su, Xi, Ge, Junbo, Leonsson-Zachrisson, Maria, Wang, Xianhong, Sun, Jing, Bai, Lu, Ma, Chang-Sheng
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Healthcare 2019
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6822841/
https://ncbi.nlm.nih.gov/pubmed/31119693
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-019-00972-z
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi